Applied Immune Technologies

Company Overview

Snapshot

Founded in February 2006 by Aya Yakobovitz, Applied Immune Technologies operated with 1–10 employees. The company secured funding across two rounds from Pontifax, raising a total of $4.4 million. In January 2016, Applied Immune Technologies was acquired by Adicet Bio.

Business overview

Applied Immune Technologies (AIT) is a drug development company focused on T-cell-receptor-like (TCRL) antibodies for therapeutic and diagnostic applications. The company's core technology platforms identify and validate novel MHC-based targets and develop human recombinant TCRL antibodies capable of binding to intracellular peptide/MHC complexes. AIT's technologies aim to create a pipeline of therapeutic TCRL antibodies for disease-specific targets not accessible to conventional antibodies, serving the Health Tech & Life Sciences sector, particularly in Pharmaceuticals, for cancer, viral, and autoimmune diseases.

Strategic signal

The acquisition of Applied Immune Technologies by Adicet Bio in January 2016 marked a significant strategic validation for AIT's T-cell-receptor-like (TCRL) antibody technology. This event signaled the potential of AIT's approach to developing novel therapeutics for cancer, viral, and autoimmune diseases, integrating its specialized platforms into a larger biopharmaceutical entity and indicating a maturation of its core technology.

Company Intelligence Q&A

What is Applied Immune Technologies' primary focus?

Applied Immune Technologies specializes in developing T-cell-receptor-like (TCRL) antibodies for therapeutic and diagnostic applications in various cancer, viral, and autoimmune diseases.

When was Applied Immune Technologies founded?

Applied Immune Technologies was founded in February 2006.

Who is a founder of Applied Immune Technologies?

Aya Yakobovitz is a founder of Applied Immune Technologies.

What was a significant corporate event for Applied Immune Technologies?

This acquisition integrated AIT's specialized platforms into Adicet Bio's biopharmaceutical operations.

Which investor participated in a funding round for Applied Immune Technologies?

Pontifax participated in a funding round for Applied Immune Technologies in April 2010.